Skip to main content
Biochemical Journal logoLink to Biochemical Journal
. 1999 Oct 15;343(Pt 2):419–423.

Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation.

D R Howlett 1, A R George 1, D E Owen 1, R V Ward 1, R E Markwell 1
PMCID: PMC1220570  PMID: 10510309

Abstract

One of the major pathological features of Alzheimer's disease is the deposition of beta-amyloid peptide (Abeta). Cellular toxicity has been shown to be associated with fibrillar forms of Abeta; preventing this fibril formation is therefore viewed as a possible method of slowing disease progression in Alzheimer's disease. With the use of a series of tetracyclic and carbazole-type compounds as inhibitors of Abeta fibril formation, we here describe a number of common structural features that seem to be associated with the inhibitory properties of these agents. Compounds such as carvedilol, rolitetracycline and daunomycin, which are shown to inhibit Abeta fibril formation, also prevent the formation of species of peptide that demonstrate biological activity in a human neuroblastoma cell line. Molecular modelling data suggest that these compounds have in common the ability to adopt a specific three-dimensional pharmacophore conformation that might be essential for binding to Abeta and preventing it from forming fibrils. Understanding such drug-peptide interactions might aid the development of disease-modifying agents.

Full Text

The Full Text of this article is available as a PDF (171.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Behl C., Davis J. B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell. 1994 Jun 17;77(6):817–827. doi: 10.1016/0092-8674(94)90131-7. [DOI] [PubMed] [Google Scholar]
  2. Camilleri P., Haskins N. J., Howlett D. R. beta-Cyclodextrin interacts with the Alzheimer amyloid beta-A4 peptide. FEBS Lett. 1994 Mar 21;341(2-3):256–258. doi: 10.1016/0014-5793(94)80467-2. [DOI] [PubMed] [Google Scholar]
  3. Camilleri P., Haskins N. J., Howlett D. R. beta-Cyclodextrin interacts with the Alzheimer amyloid beta-A4 peptide. FEBS Lett. 1994 Mar 21;341(2-3):256–258. doi: 10.1016/0014-5793(94)80467-2. [DOI] [PubMed] [Google Scholar]
  4. Feuerstein R., Yue T. L. A potent antioxidant, SB209995, inhibits oxygen-radical-mediated lipid peroxidation and cytotoxicity. Pharmacology. 1994 Jun;48(6):385–391. doi: 10.1159/000139205. [DOI] [PubMed] [Google Scholar]
  5. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995 Feb 9;373(6514):523–527. doi: 10.1038/373523a0. [DOI] [PubMed] [Google Scholar]
  6. Gianni L., Bellotti V., Gianni A. M., Merlini G. New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin. Blood. 1995 Aug 1;86(3):855–861. [PubMed] [Google Scholar]
  7. Hansen M. B., Nielsen S. E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods. 1989 May 12;119(2):203–210. doi: 10.1016/0022-1759(89)90397-9. [DOI] [PubMed] [Google Scholar]
  8. Harper J. D., Lieber C. M., Lansbury P. T., Jr Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. Chem Biol. 1997 Dec;4(12):951–959. doi: 10.1016/s1074-5521(97)90303-3. [DOI] [PubMed] [Google Scholar]
  9. Howlett D. R., Jennings K. H., Lee D. C., Clark M. S., Brown F., Wetzel R., Wood S. J., Camilleri P., Roberts G. W. Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration. 1995 Mar;4(1):23–32. doi: 10.1006/neur.1995.0003. [DOI] [PubMed] [Google Scholar]
  10. Howlett D. R., Perry A. E., Godfrey F., Swatton J. E., Jennings K. H., Spitzfaden C., Wadsworth H., Wood S. J., Markwell R. E. Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans. Biochem J. 1999 May 15;340(Pt 1):283–289. [PMC free article] [PubMed] [Google Scholar]
  11. Howlett D., Cutler P., Heales S., Camilleri P. Hemin and related porphyrins inhibit beta-amyloid aggregation. FEBS Lett. 1997 Nov 10;417(2):249–251. doi: 10.1016/s0014-5793(97)01290-8. [DOI] [PubMed] [Google Scholar]
  12. Iversen L. L., Mortishire-Smith R. J., Pollack S. J., Shearman M. S. The toxicity in vitro of beta-amyloid protein. Biochem J. 1995 Oct 1;311(Pt 1):1–16. doi: 10.1042/bj3110001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jarrett J. T., Lansbury P. T., Jr Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 1993 Jun 18;73(6):1055–1058. doi: 10.1016/0092-8674(93)90635-4. [DOI] [PubMed] [Google Scholar]
  14. Kisilevsky R., Lemieux L. J., Fraser P. E., Kong X., Hultin P. G., Szarek W. A. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med. 1995 Feb;1(2):143–148. doi: 10.1038/nm0295-143. [DOI] [PubMed] [Google Scholar]
  15. Lambert M. P., Barlow A. K., Chromy B. A., Edwards C., Freed R., Liosatos M., Morgan T. E., Rozovsky I., Trommer B., Viola K. L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6448–6453. doi: 10.1073/pnas.95.11.6448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Liu Y., Schubert D. Cytotoxic amyloid peptides inhibit cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis. J Neurochem. 1997 Dec;69(6):2285–2293. doi: 10.1046/j.1471-4159.1997.69062285.x. [DOI] [PubMed] [Google Scholar]
  17. Lorenzo A., Yankner B. A. Amyloid fibril toxicity in Alzheimer's disease and diabetes. Ann N Y Acad Sci. 1996 Jan 17;777:89–95. doi: 10.1111/j.1749-6632.1996.tb34406.x. [DOI] [PubMed] [Google Scholar]
  18. Merlini G., Ascari E., Amboldi N., Bellotti V., Arbustini E., Perfetti V., Ferrari M., Zorzoli I., Marinone M. G., Garini P. Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2959–2963. doi: 10.1073/pnas.92.7.2959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Oda T., Wals P., Osterburg H. H., Johnson S. A., Pasinetti G. M., Morgan T. E., Rozovsky I., Stine W. B., Snyder S. W., Holzman T. F. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol. 1995 Nov;136(1):22–31. doi: 10.1006/exnr.1995.1080. [DOI] [PubMed] [Google Scholar]
  20. Pollack S. J., Sadler I. I., Hawtin S. R., Tailor V. J., Shearman M. S. Sulfonated dyes attenuate the toxic effects of beta-amyloid in a structure-specific fashion. Neurosci Lett. 1995 Sep 15;197(3):211–214. doi: 10.1016/0304-3940(95)11939-t. [DOI] [PubMed] [Google Scholar]
  21. Roher A. E., Chaney M. O., Kuo Y. M., Webster S. D., Stine W. B., Haverkamp L. J., Woods A. S., Cotter R. J., Tuohy J. M., Krafft G. A. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem. 1996 Aug 23;271(34):20631–20635. doi: 10.1074/jbc.271.34.20631. [DOI] [PubMed] [Google Scholar]
  22. Salomon A. R., Marcinowski K. J., Friedland R. P., Zagorski M. G. Nicotine inhibits amyloid formation by the beta-peptide. Biochemistry. 1996 Oct 22;35(42):13568–13578. doi: 10.1021/bi9617264. [DOI] [PubMed] [Google Scholar]
  23. Seilheimer B., Bohrmann B., Bondolfi L., Müller F., Stüber D., Döbeli H. The toxicity of the Alzheimer's beta-amyloid peptide correlates with a distinct fiber morphology. J Struct Biol. 1997 Jun;119(1):59–71. doi: 10.1006/jsbi.1997.3859. [DOI] [PubMed] [Google Scholar]
  24. Soto C., Kindy M. S., Baumann M., Frangione B. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun. 1996 Sep 24;226(3):672–680. doi: 10.1006/bbrc.1996.1413. [DOI] [PubMed] [Google Scholar]
  25. Soto C., Kindy M. S., Baumann M., Frangione B. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun. 1996 Sep 24;226(3):672–680. doi: 10.1006/bbrc.1996.1413. [DOI] [PubMed] [Google Scholar]
  26. Soto C., Sigurdsson E. M., Morelli L., Kumar R. A., Castaño E. M., Frangione B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med. 1998 Jul;4(7):822–826. doi: 10.1038/nm0798-822. [DOI] [PubMed] [Google Scholar]
  27. Stine W. B., Jr, Snyder S. W., Ladror U. S., Wade W. S., Miller M. F., Perun T. J., Holzman T. F., Krafft G. A. The nanometer-scale structure of amyloid-beta visualized by atomic force microscopy. J Protein Chem. 1996 Feb;15(2):193–203. doi: 10.1007/BF01887400. [DOI] [PubMed] [Google Scholar]
  28. Teplow D. B. Structural and kinetic features of amyloid beta-protein fibrillogenesis. Amyloid. 1998 Jun;5(2):121–142. doi: 10.3109/13506129808995290. [DOI] [PubMed] [Google Scholar]
  29. Tjernberg L. O., Lilliehök C., Callaway D. J., Näslund J., Hahne S., Thyberg J., Terenius L., Nordstedt C. Controlling amyloid beta-peptide fibril formation with protease-stable ligands. J Biol Chem. 1997 May 9;272(19):12601–12605. doi: 10.1074/jbc.272.19.12601. [DOI] [PubMed] [Google Scholar]
  30. Tomiyama T., Asano S., Suwa Y., Morita T., Kataoka K., Mori H., Endo N. Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro. Biochem Biophys Res Commun. 1994 Oct 14;204(1):76–83. doi: 10.1006/bbrc.1994.2428. [DOI] [PubMed] [Google Scholar]
  31. Tomiyama T., Kaneko H., Kataoka K. i., Asano S., Endo N. Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction. Biochem J. 1997 Mar 15;322(Pt 3):859–865. doi: 10.1042/bj3220859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Walsh D. M., Lomakin A., Benedek G. B., Condron M. M., Teplow D. B. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem. 1997 Aug 29;272(35):22364–22372. doi: 10.1074/jbc.272.35.22364. [DOI] [PubMed] [Google Scholar]
  33. Wood S. J., MacKenzie L., Maleeff B., Hurle M. R., Wetzel R. Selective inhibition of Abeta fibril formation. J Biol Chem. 1996 Feb 23;271(8):4086–4092. doi: 10.1074/jbc.271.8.4086. [DOI] [PubMed] [Google Scholar]
  34. Yankner B. A., Dawes L. R., Fisher S., Villa-Komaroff L., Oster-Granite M. L., Neve R. L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science. 1989 Jul 28;245(4916):417–420. doi: 10.1126/science.2474201. [DOI] [PubMed] [Google Scholar]
  35. Yue T. L., Mckenna P. J., Lysko P. G., Gu J. L., Lysko K. A., Ruffolo R. R., Jr, Feuerstein G. Z. SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant. Eur J Pharmacol. 1994 Jan 14;251(2-3):237–243. doi: 10.1016/0014-2999(94)90405-7. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES